Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Leukaemia chronic myeloid

It is indicated in acute myelocytic leukaemia, acute lymphocytic leukaemia, chronic myeloid leukaemia (blast phase), non-Hodgkin s lymphoma in children, treatment and maintenance of meningeal neoplasms, erythroleukaemia. [Pg.375]

Rapozzi V., Burm B.E.A., CoGOi S., Van DER Marel G.A., Van Boom J.H., Quad-RiFOGLio F., XoDO L. E. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res. 2002 30 3712-3721. [Pg.174]

CLC Charcot-Leyden crystal CMC Critical micellar concentration CMI Cell mediated immunity CML Chronic myeloid leukaemia CMV Cytomegalovirus CNS Central nervous system CO Cyclooxygenase CoA Coenzyme A CoA-IT Coenzyme A - independent transacylase... [Pg.281]

Rasoul NA, Elhalawani N, Nafae MH, Elkaffash DM, Moiuad Zl. Telomerase activity in Philadelphia positive chronic myeloid leukaemia. Eg3rpt.J.lnununol. 2004 11 1 8. [Pg.170]

Campbell LJ, Fidler C, Eagleton H et al. hTERT, the catal34ic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia 2006 20 671-679. [Pg.170]

Peggs K, Mckinnon S. Imatinb mesylate - the new gold standard for treatment of chronic myeloid leukaemia. N Engl J Med 2003 348 1048-50. [Pg.726]

After oral administration, it is well absorbed and excreted in urine as methanesulfonic acid. It is mainly used in chronic myeloid leukaemia, polycythemia vera, essential thrombocythemia and myelofibrosis. [Pg.373]

Recently introduced interferon a-2b is used in chronic myeloid leukaemia, chronic hepatitis B and C. [Pg.379]

Eaves CJ, Eaves AC. Progenitor cell dynamics. In Carella AM, Daley GQ, Eaves CJ eds. Chronic myeloid leukaemia biology and treatment. London Martin Dunitz 2001 73-100. [Pg.145]

Gordon MY, Dowding CR, Riley GP et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987 328 342-344. [Pg.145]

Branford S, Cross NC, Hochhaus A et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. [Pg.146]

Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer... [Pg.147]

Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A., Griffin, J. D. Second Generation Inhibitors of Bcr-Abl for the Treatment of Imatinib-Resistant Chronic Myeloid Leukaemia. Nature Rev. 2007, 7, 345-357. [Pg.92]

O Brien SG et al (2003) Effects of imatinib mesylate (STI571, glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89 1855-1859... [Pg.240]

Singh N et al (2009) Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 65 545-549... [Pg.241]

Weisberg E et al (2007) Second generation inhibitors of BCR-ABL for the treatment of ima-tinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7 345-356... [Pg.242]

Panobinostat (LBH-589) 79 (Novartis) is being evaluated in Phase II/III trials for the treatment of refractory cutaneous T-cell lymphoma, while Phase II/III trials against refractory chronic myeloid leukaemia have been completed.191 Panobinostat 79 is also being evaluated against a variety of other... [Pg.338]

Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of 68. disease evolution in human cancer. Oncogene 2007 7 441-453. [Pg.1577]

The term myeloproliferative syndrome encompasses the following (1.) chronic myeloid leukaemia, (2.) idiopathic osteomyelofibrosis and sclerosis, (3.) polycyth-aemia vera, and (4.) essential thrombocytosis. Inter-... [Pg.812]

Fig. 38.2 Terminal blast crisis of chronic myeloid leukaemia numerous myeloid blasts in the sinusoids (HE)... Fig. 38.2 Terminal blast crisis of chronic myeloid leukaemia numerous myeloid blasts in the sinusoids (HE)...
Fig. 38.3 Splenomegaly with perisplenitis cartilaginea (sugar-icing spleen) in chronic myeloid leukaemia... Fig. 38.3 Splenomegaly with perisplenitis cartilaginea (sugar-icing spleen) in chronic myeloid leukaemia...
VassaUo C, Passamonti F, Merante S, Ardigo M, Nolh G, MangiacavaUi S, Borroni G. Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Chn Exp Dermatol 2001 26(2) 141-8. [Pg.1704]

Shepherd PC, Richards S, Allan NC. Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia. Br J Haematol 1994 86(l) 92-6. [Pg.1824]

Russo D, Candoni A, Zuffa E, Minisini R, Silvestri F, Fanin R, Zaja F, Marline Hi G, Tura S, Botta G, Baccarani M. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph-f chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. Br J Haematol 1996 94(2) 300-5. [Pg.1828]

Serrano J, Prieto E, Mazarbeitia F, Roman A, Llamas P, Tomas JF. Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT. Bone Marrow Transplant 2001 27(l) 85-7. [Pg.1829]

Shepherd PC, Fooks J, Gray R, Allan NC. Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine. Br I Haematol 1991 79(2) 185-92. [Pg.3430]

Colovic M, Jurisic V, Jankovic G, Jovanovic D, Nikolic LJ, Dimitrijevic J Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia case report and review of literature, J Clin Pathol 2006,59 879-881... [Pg.695]

NSC 94100 WR 220057 Myelobromol ) is an alkylating ANTICANCER AGENT sometimes used for chronic myeloid leukaemia. [Pg.184]

Kobashi, K. (1992) Urease activity of /fe/Zcobacterpytor/. /. Clin. Pathol.. 45.367-368. Urechollne " bethanechol chloride, urethane inn (ethyl carbamate ethyl aminoformate ethyl urethane NSC 746) was formerly used clinically as a HYPNOTIC, and can be used as a GENERAL ANAESTHETIC in small animals. It has been used as an anticanCER agent in treating chronic myeloid leukaemia. [Pg.285]

The sulphonoxyalkane myleran (busulfan 7) has distinct biological properties causing a particularly pronounced suppression of granulocytes. Mainly for this reason it has been traditional choice for chronic myeloid leukaemia but more recently other alkylating agents have proved to be just as effective in the treatment of this condition. [Pg.150]

Costello R, Lafage M, Toiron Y, Brunei V, Sainty D, Arnoulet C, et al. Philadelphia chromosome-negative chronic myeloid leukaemia a report of 14 new cases. Br J Haematol 1995 90 346-52. [Pg.1477]

Melo JV, Myint H, Galton DA, Goldman JM. P190BCR-ABL chronic myeloid leukaemia the missing linlc with chronic myelomonocytic leukaemia Leukemia 1994 8 208-11. [Pg.1480]

See other pages where Leukaemia chronic myeloid is mentioned: [Pg.44]    [Pg.273]    [Pg.285]    [Pg.251]    [Pg.956]    [Pg.334]    [Pg.396]    [Pg.811]    [Pg.813]    [Pg.608]    [Pg.147]    [Pg.171]    [Pg.238]    [Pg.325]    [Pg.591]   
See also in sourсe #XX -- [ Pg.813 ]



SEARCH



Chronic myeloid

Leukaemia

Leukaemias leukaemia

Myeloid

© 2024 chempedia.info